<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02251821</url>
  </required_header>
  <id_info>
    <org_study_id>9033</org_study_id>
    <secondary_id>NCI-2014-01882</secondary_id>
    <secondary_id>9033</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT02251821</nct_id>
  </id_info>
  <brief_title>JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis</brief_title>
  <official_title>JAK Inhibitor Prior to Allogeneic Stem Cell Transplant for Patients With Primary and Secondary Myelofibrosis: A Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well giving a JAK inhibitor before a donor stem cell
      transplant works in treating patients with myelofibrosis that developed without another
      condition (primary) or evolved from other bone marrow disorders (secondary). JAK inhibitors
      are a class of drugs that may stop the growth of abnormal cells by blocking an enzyme needed
      for cell growth. Giving a JAK inhibitor before a donor stem cell transplant may help reduce
      symptoms of myelofibrosis such as inflammation and enlargement of the spleen, improve the
      patient's general physical condition, and prevent complications from occurring after the
      transplant. Infusing healthy stem cells from a donor into the patient may help the patient's
      bone marrow work normally and make stem cells, red blood cells, white blood cells, and
      platelets. Giving a JAK inhibitor before a donor stem cell transplant may help improve
      transplant outcomes in patients with myelofibrosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To optimize the role of allogeneic transplantation for primary and secondary myelofibrosis
      (MF) in the JAK inhibitor era.

      OUTLINE:

      PART 1: Patients receive a JAK inhibitor (ruxolitinib, momelotinib, or pacritinib) orally
      (PO) twice daily (BID) from at least 8 weeks prior to the start of conditioning until best
      response through day -4 before transplantation, with a taper schedule reducing the dose every
      2-3 days beginning after day -4.

      PART 2: Patients are assigned to 1 of 2 conditioning regimens at the discretion of the
      clinical provider and Clinical Coordinators Office (CCO).

      MYELOABLATIVE CONDITIONING: Patients receive fludarabine phosphate intravenously (IV) over 1
      hour on days -8 to -6 (umbilical cord blood transplant recipients only), cyclophosphamide IV
      on days -7 and -6, and busulfan IV over 3 hours on days -5 to -2.

      REDUCED-INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV over 1 hour on days
      -6 to -2 and melphalan IV over 15-30 minutes on days -3 and -2. Patients also undergo
      total-body irradiation (TBI) on day -1 (umbilical cord blood transplant recipients only).

      TRANSPLANT: Patients undergo allogeneic hematopoietic stem cell transplant or umbilical cord
      blood transplant on day 0.

      GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS: Patients receive tacrolimus IV continuously
      (inpatients) or over 1-2 hours twice daily (BID) (outpatients) or orally (PO) BID on days -1
      to +180 (patients receiving related or unrelated stem cells) or days -3 to +180 (patients
      receiving umbilical cord blood) with taper beginning on day +56 (related donor recipients) or
      +100 (unrelated donor or umbilical cord blood recipients) in the absence of GVHD. Patients
      also receive methotrexate IV on days +1, +3, +6, and +11 (related and unrelated donor
      recipients only) or mycophenolate mofetil IV or PO every 8 hours on days 0 to +40 with taper
      to day +96 (umbilical cord blood transplant recipients only).

      After completion of study treatment, patients are followed up at 6 months, 1 year, and then
      yearly for 4 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2014</start_date>
  <primary_completion_date type="Anticipated">March 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Probability of 2-year survival in patients with myelofibrosis (MF) who receive treatment with a JAK inhibitor followed by an allogeneic transplant</measure>
    <time_frame>At 2 years</time_frame>
    <description>The exact benchmark that will be used for comparison will be determined from the mix of Dynamic International Prognostic Scoring System (DIPSS) categories among those enrolled and treated with JAK on the current trial. From this mix, an expected two-year survival will be created as a weighted average of the data cited above. This weighted average will be used as the benchmark to which the data from the current trial will be compared.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biology of post transplant disease progression</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of acute GVHD</measure>
    <time_frame>Up to 70 days post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of chronic GVHD</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of relapse</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kinetics of donor chimerism</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanism of responses to JAK inhibitors</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophil engraftment, defined as the first of 3 days absolute neutrophil count (ANC) &gt;= 500</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality (NRM)</measure>
    <time_frame>Day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality (NRM)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall incidence of primary graft failure/rejection</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall incidence of secondary graft failure/rejection</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet engraftment defined as first day of 20,000 and 50,000 with no transfusions x 7 days</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Primary Myelofibrosis</condition>
  <condition>Secondary Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>Treatment (JAK inhibitor, transplant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive a JAK inhibitor (ruxolitinib, momelotinib, or pacritinib) and undergo myeloablative or reduced-intensity conditioning followed by transplant and GVHD prophylaxis; see detailed description.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo allogeneic hematopoietic stem cell transplant</description>
    <arm_group_label>Treatment (JAK inhibitor, transplant)</arm_group_label>
    <other_name>Allogeneic Hematopoietic Cell Transplantation</other_name>
    <other_name>allogeneic stem cell transplantation</other_name>
    <other_name>HSC</other_name>
    <other_name>HSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (JAK inhibitor, transplant)</arm_group_label>
    <other_name>1, 4-Bis[methanesulfonoxy]butane</other_name>
    <other_name>BUS</other_name>
    <other_name>Bussulfam</other_name>
    <other_name>Busulfanum</other_name>
    <other_name>Busulfex</other_name>
    <other_name>Busulphan</other_name>
    <other_name>CB 2041</other_name>
    <other_name>CB-2041</other_name>
    <other_name>Glyzophrol</other_name>
    <other_name>GT 41</other_name>
    <other_name>GT-41</other_name>
    <other_name>Joacamine</other_name>
    <other_name>Methanesulfonic Acid Tetramethylene Ester</other_name>
    <other_name>Methanesulfonic acid, tetramethylene ester</other_name>
    <other_name>Mielucin</other_name>
    <other_name>Misulban</other_name>
    <other_name>Misulfan</other_name>
    <other_name>Mitosan</other_name>
    <other_name>Myeleukon</other_name>
    <other_name>Myeloleukon</other_name>
    <other_name>Myelosan</other_name>
    <other_name>Mylecytan</other_name>
    <other_name>Myleran</other_name>
    <other_name>Sulfabutin</other_name>
    <other_name>Tetramethylene Bis(methanesulfonate)</other_name>
    <other_name>Tetramethylene bis[methanesulfonate]</other_name>
    <other_name>WR-19508</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (JAK inhibitor, transplant)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (JAK inhibitor, transplant)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (JAK inhibitor, transplant)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (JAK inhibitor, transplant)</arm_group_label>
    <other_name>Alanine Nitrogen Mustard</other_name>
    <other_name>CB-3025</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-Phenylalanine mustard</other_name>
    <other_name>L-Sarcolysin</other_name>
    <other_name>L-Sarcolysin Phenylalanine mustard</other_name>
    <other_name>L-Sarcolysine</other_name>
    <other_name>Melphalanum</other_name>
    <other_name>Phenylalanine Mustard</other_name>
    <other_name>Phenylalanine Nitrogen Mustard</other_name>
    <other_name>Sarcoclorin</other_name>
    <other_name>Sarkolysin</other_name>
    <other_name>WR-19813</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (JAK inhibitor, transplant)</arm_group_label>
    <other_name>Abitrexate</other_name>
    <other_name>Alpha-Methopterin</other_name>
    <other_name>Amethopterin</other_name>
    <other_name>Brimexate</other_name>
    <other_name>CL 14377</other_name>
    <other_name>CL-14377</other_name>
    <other_name>Emtexate</other_name>
    <other_name>Emthexat</other_name>
    <other_name>Emthexate</other_name>
    <other_name>Farmitrexat</other_name>
    <other_name>Fauldexato</other_name>
    <other_name>Folex</other_name>
    <other_name>Folex PFS</other_name>
    <other_name>Lantarel</other_name>
    <other_name>Ledertrexate</other_name>
    <other_name>Lumexon</other_name>
    <other_name>Maxtrex</other_name>
    <other_name>Medsatrexate</other_name>
    <other_name>Metex</other_name>
    <other_name>Methoblastin</other_name>
    <other_name>Methotrexate LPF</other_name>
    <other_name>Methotrexate Methylaminopterin</other_name>
    <other_name>Methotrexatum</other_name>
    <other_name>Metotrexato</other_name>
    <other_name>Metrotex</other_name>
    <other_name>Mexate</other_name>
    <other_name>Mexate-AQ</other_name>
    <other_name>MTX</other_name>
    <other_name>Novatrex</other_name>
    <other_name>Rheumatrex</other_name>
    <other_name>Texate</other_name>
    <other_name>Tremetex</other_name>
    <other_name>Trexeron</other_name>
    <other_name>Trixilem</other_name>
    <other_name>WR-19039</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Momelotinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (JAK inhibitor, transplant)</arm_group_label>
    <other_name>CYT387</other_name>
    <other_name>GS-0387</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Treatment (JAK inhibitor, transplant)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pacritinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (JAK inhibitor, transplant)</arm_group_label>
    <other_name>Oral JAK2 Inhibitor SB1518</other_name>
    <other_name>SB1518</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (JAK inhibitor, transplant)</arm_group_label>
    <other_name>INCB-18424</other_name>
    <other_name>INCB18424</other_name>
    <other_name>Oral JAK Inhibitor INCB18424</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Treatment (JAK inhibitor, transplant)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Fujimycin</other_name>
    <other_name>Hecoria</other_name>
    <other_name>Prograf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Treatment (JAK inhibitor, transplant)</arm_group_label>
    <other_name>TOTAL BODY IRRADIATION</other_name>
    <other_name>Whole-Body Irradiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Umbilical Cord Blood Transplantation</intervention_name>
    <description>Undergo umbilical cord blood transplant</description>
    <arm_group_label>Treatment (JAK inhibitor, transplant)</arm_group_label>
    <other_name>Cord Blood Transplantation</other_name>
    <other_name>UCB transplantation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        PART 1:

          -  PART 1: Disease criteria

               -  Diagnosis of primary MF (PMF) as defined by the 2008 World Health Organization
                  classification system or diagnosis of secondary MF as defined by the
                  International Working Group (IWG) for Myeloproliferative Neoplasms Research and
                  Treatment criteria

               -  Patients meeting the criteria for intermediate-1, intermediate-2 or high-risk
                  disease by the Dynamic International Prognostic Scoring System (DIPSS) or
                  DIPSS-plus scoring system

          -  PART 1: Ability to understand and the willingness to sign a written informed consent
             document

        PART 2:

          -  PART 2: Meeting criteria for 1st phase as above, at time of initiation of JAK
             inhibitor, including ability to understand and willingness to sign a written informed
             consent; patients arriving to our institution for transplant and not enrolled in Part
             1 may still be enrolled in Part 2 if Part 1 criteria met; these patients will have
             Part 1 endpoints transcribed from medical records

          -  PART 2: Received JAK inhibitor for at least 8 weeks immediately prior to conditioning
             and be able to continue until Day -4 pre-transplant

          -  PART 2: Performance status score

               -  Karnofsky &gt;= 70

          -  PART 2: Calculated creatinine clearance using the Cockcroft-Gault formula or 24 hr
             urine creatinine clearance must be &gt; 60 ml/min

          -  PART 2: Total serum bilirubin must be &lt; 3 mg/dL unless the elevation is thought to be
             due to Gilbert's disease or hemolysis

          -  PART 2: Transaminases must be &lt; 3 x the upper limit of normal

          -  PART 2: Patients with clinical or laboratory evidence of liver disease will be
             evaluated for the cause of liver disease, its clinical severity in terms of liver
             function, and the degree of portal hypertension; patients with fulminant liver
             failure, cirrhosis with evidence of portal hypertension or bridging fibrosis,
             alcoholic hepatitis, hepatic encephalopathy, or correctable hepatic synthetic
             dysfunction evidenced by prolongation of the prothrombin time, ascites related to
             portal hypertension, bacterial or fungal abscess, biliary obstruction, chronic viral
             hepatitis with total serum bilirubin &gt; 3 mg/dL, and symptomatic biliary disease will
             be excluded

          -  PART 2: Diffusing capacity of the lung for carbon monoxide (DLCO) corrected &gt; 60%
             normal

               -  May not be on supplemental oxygen

          -  PART 2: Left ventricular ejection fraction &gt; 40% OR

          -  PART 2: Shortening fraction &gt; 26%

          -  PART 2: Comorbidity Index &lt; 5 at the time of pre-transplant evaluation

        DONOR:

          -  DONOR: Human leukocyte antigen (HLA)-matched or 1 antigen mismatched sibling donor

          -  DONOR: 10 of 10 HLA-matched or 1 allele mismatched (9 of 10) unrelated donor

          -  DONOR: Peripheral blood is preferred over bone marrow for non-umbilical cord blood
             recipients

          -  DONOR: Umbilical cord blood units will be selected according to the following
             umbilical cord blood graft selection criteria; one or 2 cord blood (CB) units may be
             used to achieve the required cell dose

          -  DONOR: The CB graft(s) must be matched at 4-6 HLA-A, B, DR Beta 1 (DRB1) loci with the
             recipient and therefore may include 0-2 mismatches at the A or B or DRB1 loci; unit
             selection will be based on cryopreserved nucleated cell dose and intermediate
             resolution A, B antigen and DRB1 allele typing for determination of HLA-match; while
             HLA-C antigen/allele level typing is not considered in the matching criteria, if
             available, it may be used to optimize unit selection

          -  DONOR: Selection of two CB units is allowed to provide sufficient cell dose (see below
             for algorithm to determine single versus double unit transplant); when multiple units
             are selected, the following rules apply:

               -  The CB unit with the least HLA disparity (with the patient) will be selected
                  first (i.e., selection priority is 6/6 match &gt; 5/6 match &gt; 4/6 match); additional
                  CB units then may be selected to achieve the required cell dose, as outlined
                  below; if a second unit is required, this unit will be the unit that most closely
                  HLA matches the patient and meets minimum size criteria outlined below of at
                  least 1.5 x 10^7 total nucleated cells (TNC)/kg (i.e. a smaller, more closely
                  matched unit will be selected over a larger, less well matched unit as long as
                  minimum criteria are met)

               -  If two CB units are used:

                    -  The total cell dose of the combined units must be at least 3.0 x 10^7 TNC
                       per kilogram recipient weight

                    -  Each CB unit MUST contain at least 1.5 x 10^7 TNC per kilogram recipient
                       weight

               -  Algorithm for determining single versus double unit cord blood transplant:

                    -  Match grade 6/6: TNC dose &gt;= 2.5 x 10^7/kg

                    -  Match grade 5/6, 4/6: TNC dose &gt;= 4.0 (+/- 0.5) x 10^7/kg

          -  DONOR: General comments:

               -  Units will be selected first based on the TNC dose and HLA matching

               -  Cluster of differentiation (CD)34+ cell dose will not be used for unit selection
                  unless 2 units of equal HLA-match grade and similar TNC dose (+/- 0.5 x 10^7
                  TNC/kg) are available; in this case, the unit with the larger CD34+ cell dose (if
                  data available) should be selected

               -  A CB unit that is 5/6 mismatched but homozygous at the locus of mismatch should
                  be chosen over a 5/6 unit with bidirectional mismatch even if the latter unit is
                  larger (has more cells); this also applies to 4/6 units; this is only applicable
                  to choosing units within a given match grade

               -  Other factors to be considered:

                    -  Within the same HLA match grade, matching at DR takes preference

                    -  Cord blood banks located in the United States are preferred

               -  Up to 5% of the cord blood product(s), when ready for infusion, may be withheld
                  for research purposes as long as thresholds for infused TNC dose are met; these
                  products will be used to conduct studies involving the kinetics of engraftment
                  and immunobiology of double cord transplantation

        Exclusion Criteria:

        PART 1:

          -  PART 1: Evidence of human immunodeficiency virus (HIV) infection or known HIV positive
             serology

          -  PART 1: Uncontrolled viral, bacterial, or fungal infections at the time of study
             enrollment

          -  PART 1: History of prior allogeneic transplant

          -  PART 1: Pregnant or breastfeeding

        PART 2:

          -  PART 2: Uncontrolled viral or bacterial infection at the time of study enrollment

          -  PART 2: Active or recent (prior 6 month) invasive fungal infection without infectious
             disease (ID) consult and approval

          -  PART 2: History of HIV infection

          -  PART 2: Pregnant or breastfeeding

          -  PART 2: Patients without an HLA-identical or 1-allele-mismatched related donor or
             unrelated donor or umbilical cord blood units that meet transplant criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rachel Salit</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel B. Salit</last_name>
      <phone>206-667-1317</phone>
      <email>rsalit@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Rachel B. Salit</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2014</study_first_submitted>
  <study_first_submitted_qc>September 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2014</study_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Mechlorethamine</mesh_term>
    <mesh_term>Nitrogen Mustard Compounds</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

